# Exploring Preferences for Long-Acting Antiretroviral Therapies (LA-ART) in a Community-Based Sample of Priority Populations Living with HIV Who are Disproportionately Affected

Source: https://welltoldgrants.com/grants/rfa-ps-23-003-exploring-preferences-for-long-acting-antiretroviral/  
Official notice: https://www.grants.gov/search-results-detail/343368

> Centers for Disease Control and Prevention - ERA offered grants of up to $333,000 (at least $300,000) to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. It expected to make one award worth $1.0 million in total. Applications closed on March 17, 2023.

| Field | Value |
|---|---|
| Opportunity number | RFA-PS-23-003 |
| Agency | Centers for Disease Control and Prevention - ERA |
| Status | Forecast |
| Deadline | March 17, 2023 |
| Award ceiling | $333,000 |
| Award floor | $300,000 |
| Expected awards | 1 |
| Total funding | $1.0 million |
| Cost sharing | not required |
| Assistance Listings | 93.084 |

## Who can apply

- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities/Indian housing authorities
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- For profit organizations other than small businesses
- Small businesses

N/A

## What the grant funds

The purpose of this notice of funding opportunity is to support formative research on cis-gender Black women with HIV (CgBWH) and their acceptance and perceived barriers and facilitators of using current and future long-acting antiretroviral therapies. Use of a qualitative research design is expected to yield details and nuances of decision-making and circumstances related to uptake of Long-Acting Antiretroviral Therapies (LA-ART) that may not be possible to gather through quantitative data collection methods alone. This exploratory qualitative approach will offer a unique source of information about LA-ART from the perspectives and experiences of CgBWH, including barriers and facilitators to uptake and use and individual and systemic supports needed to facilitate delivery of this therapy. The findings of this research are expected to strengthen adherence to ART for this population and impact the racial/ethnic disparities in viral suppression observed for this group.

## Questions people ask

### Is RFA-PS-23-003 still open?

No. It closed on March 17, 2023. A newer notice is open: PA-27-100, due dates in the notice, expires April 5, 2027.

### Who can apply for Exploring Preferences for Long-Acting Antiretroviral Therapies (LA-ART) in a Community-Based Sample of Priority Populations Living with HIV Who are Disproportionately Affected?

Centers for Disease Control and Prevention - ERA accepted applications from nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. The notice adds further conditions, so read its eligibility section.

### What is the deadline for Exploring Preferences for Long-Acting Antiretroviral Therapies (LA-ART) in a Community-Based Sample of Priority Populations Living with HIV Who are Disproportionately Affected?

Closed March 17, 2023. Applications are no longer accepted; the program's newer notices are on this page when there are any.

### How much funding is available?

Awards of up to $333,000 each. About $1.0 million in total for one award.

### Who has won Prevention of Disease, Disability, and Death by Infectious Diseases   grants before?

The largest recipients over five fiscal years were Puerto Rico Science, Technology, and Research Trust, Massachusetts Department of Public Health, Emory University. The program made 128 awards worth $241 million in that time.